Study Finder

Only with the aid of clinical trials is it possible to ascertain how to improve efficacy and collect data on the impact of adverse effects. Every well-conducted study, every participating site and patient contribute to improved care for tumor patients.

If you are interested in participating in a study, please don’t hesitate to contact us.

ADAPTlate

Study

Breast Cancer

Recruitment

Closed

Open

INDICATION

Breast Cancer

HR+/HER2-

after completed local treatment

THERAPY

Abemaciclib

FOR CENTERS

Closed

FOR PATIENTS

Open

STATUS

Recruitment

ARIADNE

NIS

Lymphatic Neoplasia

Recruitment

Closed

Open

INDICATION

Lymphatic Neoplasia

Waldenström macroglobulinemia

1st line or ≤ 2nd line palliative

THERAPY

Zanubrutinib

FOR CENTERS

Closed

FOR PATIENTS

Open

STATUS

Recruitment

AZURITE

Registry

Colorectal Cancer

Treatment

Closed

INDICATION

Colorectal Cancer

metastasized

1st line

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Treatment

BERING

NIS

Colorectal Cancer

Recruitment

Open

INDICATION

Colorectal Cancer

metastasized, BRAFV600E-mutation

1st line

THERAPY

Encorafenib + Cetuximab

FOR CENTERS

Open

FOR PATIENTS

Open

STATUS

Recruitment

CARAT

Registry

Urogenital Tumors

Recruitment

Open

INDICATION

Urogenital Tumors

Renal Cell Carcinoma

metastatic / locally advanced and inoperable

1st line

THERAPY

no specification

FOR CENTERS

Open

FOR PATIENTS

Open

STATUS

Recruitment

CARO

NIS

Multiple Myeloma

Recruitment

Closed

Open

INDICATION

Multiple Myeloma ≥ 2nd line

THERAPY

carfilzomib + lenalidomide + dexamethasone or CAR/DEX

FOR CENTERS

Closed

FOR PATIENTS

Open

STATUS

Recruitment

CRISP

Registry

Lung Cancer

Recruitment

Closed

Open

INDICATION

Lung Cancer

NSCLC, stage II - IV

1st line

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Open

STATUS

Recruitment

FIRST-NIS

NIS

Multiple Myeloma

Follow-Up

Closed

INDICATION

Multiple Myeloma 1st line

THERAPY

lenalidomide (Revlimid®) + dexamethasone

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

INGE-B

Study

Breast Cancer

Treatment

Closed

INDICATION

Breast Cancer

HR-positive / HER2-negative, inoperable or metastatic

≥ 1st line

THERAPY

1st line: palbociclib + aromatase inhibitor (letrozole / anastrozole / exemestane) or fulvestrant
≥ 2nd line: palbociclib + letrozole or fulvestrant

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Treatment

MANTA

Study

Breast Cancer

Follow-Up

Closed

INDICATION

Breast Cancer

HER2/neu-negative, metastatic or locally advanced

2nd line

THERAPY

fulvestrant + AZD2014

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

MYRIAM

Registry

Multiple Myeloma

Recruitment

Open

INDICATION

Multiple Myeloma 1st line, 2nd line. 3rd line

THERAPY

no specification

FOR CENTERS

Open

FOR PATIENTS

Open

STATUS

Recruitment

OPAL

Registry

Breast Cancer

Recruitment

Open

INDICATION

Breast Cancer

metastatic / locally advanced and inoperable

1st line

THERAPY

no specification

FOR CENTERS

Open

FOR PATIENTS

Open

STATUS

Recruitment

PERFORM

NIS

Breast Cancer

Recruitment

Open

INDICATION

Breast Cancer

HR+/HER2-HR+/HER2-locally advanced, unresectable or metastatic

1st line

THERAPY

Palbociclib + aromatase inhibitor or Palbociclib + Fulvestrant

FOR CENTERS

Open

FOR PATIENTS

Open

STATUS

Recruitment

PreCycle

Study

Breast Cancer

Follow-Up

Closed

INDICATION

Breast Cancer

HR pos / HER2 neg, metastasized / locally advanced & inoperable

1st line to max. ≤ 4th line (max. 1 CTx and/or 2 HTx)

THERAPY

Palbociclib + aromatase inhibitor or Palbociclib + Fulvestrant

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

REALTRK

Registry

Precision Oncology

Recruitment

Open

INDICATION

Precision Oncology

Solid tumor with NTRK gene fusion, locally advanced or metastatic

no specification

THERAPY

no specification

FOR CENTERS

Open

FOR PATIENTS

Open

STATUS

Recruitment

RIBBIT

Study

Breast Cancer

Follow-Up

Closed

INDICATION

Breast Cancer

HR-positive / HER2-negative, with visceral metastases, postmenopausal

1st line

THERAPY

ribociclib + aromatase inhibitor vs. paclitaxel +/- bevacizumab

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

SAPHIR

Registry

Gastric Cancer Esophageal Cancer

Recruitment

Open

INDICATION

Gastric Cancer

metastatic

Esophageal Cancer

metastatic

1st line

THERAPY

no specification

FOR CENTERS

Open

FOR PATIENTS

Open

STATUS

Recruitment

SMARAGD

Registry

Ovarian Cancer Endometrial Cancer

Recruitment

Open

INDICATION

Ovarian Cancer

FIGO Stadium IIb-I

Endometrial Cancer

FIGO Stadium III-IV

OC: At the start of initial systemic therapy or at first relapse diagnosis. EC: 1st line

THERAPY

no specification

FOR CENTERS

Open

FOR PATIENTS

Open

STATUS

Recruitment

TRACE

NIS

Breast Cancer

in Preparation

Open

INDICATION

Breast Cancer Cohort 1: 1st line or 2nd line palliative Cohort 2: 3rd line or 4th line palliative

THERAPY

Tucatinib + Trastuzumab + Capecitabin

FOR CENTERS

Open

FOR PATIENTS

Open

STATUS

in Preparation

Tumor Registry Pancreatic Cancer

Registry

Pancreatic Cancer

Recruitment

Closed

Open

INDICATION

Pancreatic Cancer

metastatic / advanced and inoperable

1st line

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Open

STATUS

Recruitment

VALIDATE

NIS

Colorectal Cancer

Treatment

Closed

INDICATION

Colorectal Cancer

metastatic, RAS wild-type

1st line

THERAPY

panitumumab + FOLFIRI or FOLFOX

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Treatment